US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class II · Moderate risk Terminated

Launch Sequence Capsules

Reason Marketed Without An Approved NDA/ANDA: Unapproved Drug based on label claims.

Loud Muscle Science D-1339-2022
Class I · High risk Terminated

Launch Sequence Aphrodisia Capsules

Reason Marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Loud Muscle Science D-1338-2022
Class I · High risk Terminated

Launch Sequence Euphoria Capsules

Reason Marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Loud Muscle Science D-1337-2022
Class I · High risk Terminated

Launch Sequence Capsules

Reason Marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Loud Muscle Science D-1336-2022
Class II · Moderate risk Terminated

Divalproex Sodium Delayed-Release Tablets

Reason Failed Dissolution Specifications: Failure occurred during routine stability testing of dissolution test.

Sun Pharmaceutical Industries INC NDC 62756-798-88 D-1291-2022
Class I · High risk Terminated

Nifedipine WSP 0.2% Ointment

Reason Subpotent and Superpotent Drug

Valor Compounding Pharmacy, Inc DBA Valor Compounding Pharmacy D-1286-2022
Class II · Moderate risk Terminated

Hydrogen Peroxide Topical Solution

Reason Labeling: Label Mix-Up-The primary label on the front of the bottles have Hydrogen Peroxide affixed to the front and back of the containers. However, the product inside the bottle is 70% Isopropyl Alcohol.

Vi-Jon, LLC NDC 59779-871-45 D-1191-2022
Class II · Moderate risk Ongoing

Daytrana

Reason Defective Delivery System: Customer complaints received for ripping patches and tight release/adhesive transfer.

Noven Pharmaceuticals Inc NDC 68968-5552-3 D-1169-2022